Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rationale and Design of Psoriasis/PsA Registry

BMC Dermatol; ePub 2017 Aug 16; Schneeweiss, et al

Researchers have developed a single-center, longitudinal psoriasis/psoriatic arthritis (PsA) registry to better define longitudinal disease characteristics, perform biomarker studies, and examine treatment trends. Psoriasis and PsA, according to researchers, are related conditions with poorly defined transition among them, risk factors for progression, complex treatment algorithms, and biomarkers for treatment response and long-term outcomes. Recognizing this, they developed the Brigham Cohort, including biorepository, which captures relevant disease markers and treatment choices in a circumscribed population with a defined catchment area. They searched electronic medical records (EMR) for patients with visits in the last year for psoriasis or PsA and formed the potentially eligible registry population. Baseline patient and provider questionnaires were developed using standardized measures, including demographics, comorbidities, medications, specific disease characteristics, functional status, quality of life, mental health, and resource use. Some key findings:

  • Searching the Brigham EMR system from 2013 through 2014 revealed 1,694 patients with psoriasis and 1,028 with PsA.
  • Their mean age was 55 years and 53% were female.
  • Of these, 17% had diabetes, 38% hyperlipidemia, and 45% hypertension.
  • The median body mass index (BMI) was 29.6.


Schneeweiss M, Merola JF, Karlson EW, Solomon DH. Rationale and design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). [Published online ahead of print August 16, 2017]. BMC Dermatol. doi:10.1186/s12895-017-0063-8.